This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
J&J (JNJ) to Commence Pharma Q4 Earnings: What to Expect
by Zacks Equity Research
J&J's (JNJ) Pharmaceuticals segment is likely to face difficult comparisons in fourth quarter.
3 Weight-Loss Stocks in Focus on Rising Obesity Fears
by Sreyoshi Mukherjee
Three companies with bright prospects as the U.S. weight-loss industry keeps up its battle against obesity.
Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed the most recent trading day at $129.36, moving +0.84% from the previous trading session.
Johnson & Johnson (JNJ) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Johnson & Johnson (JNJ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
A Look at Dow ETF Ahead of Q4 Earnings
by Sweta Killa
Let's delve into the Q4 earnings picture that will likely set up the movement of Dow Jones ETF in the coming days.
4 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2019
by Kinjel Shah
Here we present four therapeutic areas whose pipeline developments are expected to garner a lot of interest in 2019.
Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed the most recent trading day at $128.93, moving -0.79% from the previous trading session.
Karyopharm Files MAA for Myeloma Candidate Selinexor in EU
by Zacks Equity Research
Karyopharm (KPTI) tenders a marketing application to European regulatory authority with the purpose of seeking an approval for selinexor to address patients with penta-refractory multiple myeloma.
The Zacks Analyst Blog Highlights: Visa, Coca-Cola, AbbVie, Johnson & Johnson and Duke Energy
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Visa, Coca-Cola, AbbVie, Johnson & Johnson and Duke Energy
Top Analyst Reports for Visa, Coca-Cola & AbbVie
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Visa (V), Coca-Cola (KO) and AbbVie (ABBV).
AbbVie (ABBV) Inks Immunotherapy Deal with Private Biotech
by Zacks Equity Research
AbbVie (ABBV) inks deal with Tizona Therapeutics, to develop and commercialize CD39-targeted therapeutics, including TTX-030, which is a first-in-class antibody for the treatment of cancer.
Pfizer Begins Pivotal Study on Alopecia Areata Candidate
by Zacks Equity Research
Pfizer (PFE) initiates a pivotal phase IIb/III study to evaluate JAK3 inhibitor, PF-06651600, for treating moderate to severe alopecia areata.
Johnson & Johnson (JNJ) Stock Moves -1.59%: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed at $125.72 in the latest trading session, marking a -1.59% move from the prior day.
VIVUS (VVUS) Banks on New Drug Pancreaze, Qsymia Lacks Luster
by Zacks Equity Research
Although VIVUS (VVUS) is struggling with its legacy products, promotional initiatives and addition of cash-flow positive assets bode well for the company.
Portola Up as Large-Scale Andexxa Production Gets FDA Nod
by Zacks Equity Research
Portola Pharmaceuticals (PTLA) announces FDA approval for large-scale Generation II manufacturing process for Andexxa to support commercial launch expected this month.
Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed the most recent trading day at $127.36, moving +0.51% from the previous trading session.
Forget J&J, Buy These 3 Big Drug Stocks Instead in 2019
by Kinjel Shah
J&J's (JNJ) stock has declined more than 14% since Reuters reported that it knew for decades that its baby powders contained asbestos. It is better to avoid the stock and invest in these three big drug stocks instead.
The Zacks Analyst Blog Highlights: Amazon, Johnson & Johnson, Home Depot, Medtronic and Paychex
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amazon, Johnson & Johnson, Home Depot, Medtronic and Paychex
Bayer (BAYRY) Faces Generic Threat & Rising Competition
by Zacks Equity Research
Bayer (BAYRY) is facing generic threats/competition for many of its products. The genericization of key drugs will negatively impact revenues.
AbbVie Partners Lupin to Boost Hematological Cancer Pipeline
by Zacks Equity Research
AbbVie (ABBV) enters into partnership with India-based Lupin, gaining exclusive rights to develop and commercialize the latter's investigational MALT1 inhibitors for hematological cancers.
Top Stock Reports for Amazon, Johnson & Johnson & Home Depot
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Amazon (AMZN), Johnson & Johnson (JNJ) and Home Depot (HD).
The Zacks Analyst Blog Highlights: Alphabet, Walgreens Boots, Johnson & Johnson and Amazon
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alphabet, Walgreens Boots, Johnson & Johnson and Amazon
Equity Markets Have Their Worst Week in Ten Years
by David Borun
Recession fear and a Fed rate hike contribute to losses not seen since 2008
Alphabet Ties Up with Walgreens, Boosts Healthcare Presence
by Zacks Equity Research
Alphabet's (GOOGL) Verily joins forces with Walgreens Boots Alliance to trim the healthcare cost for the patients with the aid of technology.
Pharma Stock Roundup: GSK, PFE Ink Consumer Health JV, JNJ Hit by Talc Allegations
by Zacks Equity Research
Glaxo (GSK) and Pfizer (PFE) agree to merge their consumer healthcare units into a new JV. J&J stock hit by reports alleging it of being aware of the presence of asbestos in baby powder.